Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.
ORIGINAL SOURCE →via Bloomberg Markets
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · IN
- [CONFLICT] Mani Shankar Aiyar blasts Congress over alliance with Vijay's TVK: ‘Political stupidity, immorality’
- [ENERGY] More Than 40 India-Bound Ships Remain Trapped Near Hormuz
- [ENERGY] More Than 40 India-Bound Ships Remain Trapped Near Hormuz - Crude Oil Prices Today | OilPrice.com
- [ENERGY] India power companies strained as big users source own electricity
- [AVIATION] India eyes fractional aircraft ownership policy
- [CONFLICT] Adobe opens new India office